Business Description
Sage Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US78667J1088
Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.4 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -4.14 | |||||
| Beneish M-Score | 4.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -59 | |||||
| 3-Year Book Growth Rate | -27.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 31.02 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 47.51 | |||||
| 9-Day RSI | 48.38 | |||||
| 14-Day RSI | 46.43 | |||||
| 3-1 Month Momentum % | -12.47 | |||||
| 6-1 Month Momentum % | -41.67 | |||||
| 12-1 Month Momentum % | -68.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.02 | |||||
| Quick Ratio | 10.02 | |||||
| Cash Ratio | 9.42 | |||||
| Days Payable | 363.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | 1.33 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.75 | |||||
| Operating Margin % | -350.06 | |||||
| Net Margin % | -317.29 | |||||
| FCF Margin % | -300.74 | |||||
| ROE % | -48.2 | |||||
| ROA % | -43.07 | |||||
| ROIC % | -962.91 | |||||
| 3-Year ROIIC % | -9331.36 | |||||
| ROC (Joel Greenblatt) % | -5468.89 | |||||
| ROCE % | -53.03 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.15 | |||||
| PB Ratio | 0.62 | |||||
| Price-to-Tangible-Book | 0.62 | |||||
| EV-to-EBIT | 0.59 | |||||
| EV-to-EBITDA | 0.59 | |||||
| EV-to-Forward-EBITDA | -0.2 | |||||
| EV-to-Revenue | -2.05 | |||||
| EV-to-Forward-Revenue | 2.01 | |||||
| EV-to-FCF | 0.68 | |||||
| Price-to-GF-Value | 0.04 | |||||
| Price-to-Net-Current-Asset-Value | 0.64 | |||||
| Price-to-Net-Cash | 0.68 | |||||
| Earnings Yield (Greenblatt) % | 169.49 | |||||
| FCF Yield % | -93.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sage Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 97.506 | ||
| EPS (TTM) (€) | -5.109 | ||
| Beta | -0.25 | ||
| 3-Year Sharpe Ratio | -0.99 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | 50.82 | ||
| 14-Day RSI | 46.43 | ||
| 14-Day ATR (€) | 0.222844 | ||
| 20-Day SMA (€) | 5.07775 | ||
| 12-1 Month Momentum % | -68.67 | ||
| 52-Week Range (€) | 3.986 - 24.8 | ||
| Shares Outstanding (Mil) | 61.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sage Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sage Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sage Therapeutics Inc Frequently Asked Questions
What is Sage Therapeutics Inc(STU:SG7)'s stock price today?
The current price of STU:SG7 is €5.25. The 52 week high of STU:SG7 is €24.80 and 52 week low is €3.99.
When is next earnings date of Sage Therapeutics Inc(STU:SG7)?
The next earnings date of Sage Therapeutics Inc(STU:SG7) is 2025-02-14 Est..
Does Sage Therapeutics Inc(STU:SG7) pay dividends? If so, how much?
Sage Therapeutics Inc(STU:SG7) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers